Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Syndax Pharmaceuticals and Ventana Medical Systems have signed a deal to develop a companion diagnostic assay to select patients with non-small cell lung cancer (NSCLC) for treatment with erlotinib and Syndax's entinostat.
Subscribe to our email newsletter
Entinostat is a novel, oral small molecule inhibitor of class I histone deacetylases, key enzymes that alter the structure of chromatin to control gene expression.
Data from Encore 401 indicated that a subset of advanced non-small cell lung cancer patients expressing high levels of the protein e-cadherin in their tumors derived a 4-month survival advantage with the combination treatment versus erlotinib plus placebo.
Syndax president and CEO Joanna Horobin said the company is pleased to partner with a major provider of diagnostic solutions for patients as the development of entinostat in NSCLC progresses.
"In ENCORE 401, a randomized, phase 2 study comparing erlotinib plus entinostat to erlotinib plus placebo, the subset of patients with tumors expressing high levels of the protein E-cadherin experienced a more favorable overall survival and we therefore intend to select this patient population in the confirmatory study planned to start in the second half of the year," Horobin added.